Abstract:Background: The dynamics of vaccination against SARS-CoV-2 are complicated by age-dependent factors, changing levels of infection, and the relaxation of non-pharmaceutical interventions (NPIs) as the perceived risk declines, necessitating the use of mathematical models. Our aims were to use epidemiological data from the UK together with estimates of vaccine efficacy to predict the possible long-term dynamics of SARS-CoV-2 under the planned vaccine rollout. Methods: In this study, we used a mathematical model structured by age and UK region, fitted to a range of epidemiological data in the UK, which incorporated the planned rollout of a two-dose vaccination programme (doses 12 weeks apart, protection onset 14 days after vaccination). We assumed default vaccine uptake of 95% in those aged 80 years and older, 85% in those aged 50-79 years, and 75% in those aged 18-49 years, and then varied uptake optimistically and pessimistically. Vaccine efficacy against symptomatic disease was assumed to be 88% on the basis of Pfizer-BioNTech and Oxford-AstraZeneca vaccines being administered in the UK, and protection against infection was varied from 0% to 85%. We considered the combined interaction of the UK vaccination programme with multiple potential future relaxations (or removals) of NPIs, to predict the reproduction number (R) and pattern of daily deaths and hospital admissions due to COVID-19 from January, 2021, to January, 2024. Findings: We estimate that vaccination alone is insufficient to contain the outbreak. In the absence of NPIs, even with our most optimistic assumption that the vaccine will prevent 85% of infections, we estimate R to be 1·58 (95% credible intervals [CI] 1·36-1·84) once all eligible adults have been offered both doses of the vaccine. Under the default uptake scenario, removal of all NPIs once the vaccination programme is complete is predicted to lead to 21 400 deaths (95% CI 1400-55 100) due to COVID-19 for a vaccine that prevents 85% of infections, although this number increases to 96 700 deaths (51 800-173 200) if the vaccine only prevents 60% of infections. Although vaccination substantially reduces total deaths, it only provides partial protection for the individual; we estimate that, for the default uptake scenario and 60% protection against infection, 48·3% (95% CI 48·1-48·5) and 16·0% (15·7-16·3) of deaths will be in individuals who have received one or two doses of the vaccine, respectively. Interpretation: For all vaccination scenarios we investigated, our predictions highlight the risks associated with early or rapid relaxation of NPIs. Although novel vaccines against SARS-CoV-2 offer a potential exit strategy for the pandemic, success is highly contingent on the precise vaccine properties and population uptake, both of which need to be carefully monitored. Funding: National Institute for Health Research, Medical Research Council, and UK Research and Innovation.

Managing the risk of COVID-19 via vaccine passports: Modeling economic and policy implications

Cost-Effectiveness Analysis of COVID-19 Vaccination : A review of some Vaccination Models

Do COVID-19 Vaccination Policies Backfire? The Effects of Mandates, Vaccination Passports, and Financial Incentives on COVID-19 Vaccination

Evaluating vaccination timing, hesitancy and effectiveness to prevent future outbreaks: insights from COVID-19 modelling and transmission dynamics

Epidemiological contemplation for a currently pragmatic COVID-19 health passport: a perspective

When the market got the first dose: Stock volatility and vaccination campaign in COVID-19 period

Vaccine Credential Technology Principles

Effectiveness of vaccination and quarantine policies to curb the spread of COVID-19

Vaccination with vector type vaccines – is it worth the risk?

Vaccine Impact Bonds: An Alternative Way of Allocating the Economic Risks of Mass Vaccination Programs

Modeling Framework to Evaluate Vaccine Strategies against the COVID-19 Pandemic

Impact of Interventional Policies Including Vaccine on Covid-19 Propagation and Socio-Economic Factors

Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study

COVID-19 vaccine and risk-taking

What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult Individual Perspective?

Untangling the changing impact of non-pharmaceutical interventions and vaccination on European COVID-19 trajectories

Role of modelling in COVID-19 policy development

Political ideology and vaccination willingness: implications for policy design

Ethical implications of COVID-19 management—is freedom a desired aim, or a desired means to an end?

COVID-19 epidemic and mitigation policies: Positive and normative analyses in a neoclassical growth model

Quantifying the Impact of Public Perceptions on Vaccine Acceptance Using Behavioral Economics